WebINCB081776, INCB 081776, AXL/MER inhibitor, INCB081776 is a potent and selective dual inhibitor of AXL and MERTK with IC50 of 16 and 14 nM respectively, 30-fold selectivity … WebFind technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated …
incb081776 - My Cancer Genome
WebA Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies STATUS Recruiting End date Nov 28, 2024 participants needed 140 sponsor … WebIncb081776 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating incb081776, 1 is phase 1 (1 open). Deficient DNA Mismatch Repair … the barney\u0027s adventure bus part 7
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 …
WebClinical trial for Advanced Solid Tumors , A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies WebNov 5, 2024 · Methods: INCB 57643-103 (NCT04279847) is a phase 1, single-arm, open-label, two-part dose confirmation and expansion study evaluating INCB057643 in patients with measurable histologically or cytologically confirmed (World Health Organization criteria 2016), relapsed or refractory primary MF or secondary MF (post-polycythemia vera, post … WebAug 25, 2024 · NCT03522142 Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative Hormone Mutations: ER+, PR+ Other Mutations: Breast Cancer Tissue: Recruitment Status: Recruiting Phase 1 Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor Key Eligibility Criteria: the gwinn estate cleveland ohio